<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130914014649N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-16</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the Effects of Extended-Release and Immediate-Release Metformin on Blood Sugar Control in Women with Gestational Diabetes</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Efficacy of Extended-released Versus Immediate-release Metformin on Glycemic Control in Women with Gestational Diabetes Mellitus:A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>37</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94617</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, eligiblepatients will be randomly assigned to two groups receiving either extended-released metformin (xr) or immediate-released metformin (ir) after providing informed consent. Block randomization with a1:1 allocation ratio will be used. The random allocation sequence will be generated using the online Sealed Enveloped randomization tool with block sizes of 4 and 6.</study_design>
      <phase>1</phase>
      <hc_freetext>Gestational Diabetes Mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Pregnant women diagnosed with gestational diabetes mellitus will receive extended-release metformin (XR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery. Intervention 2: Intervention group:  Pregnant women diagnosed with gestational diabetes mellitus will receive immediate-release metformin (IR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to the need to protect patient confidentiality, a decision regarding individual participant data sharing will be made after study completion in consultation with the research team.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Motevasselian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmadabad Street, Ghaem Hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9175835743</zip>
        <telephone>+98 51 3840 9169</telephone>
        <email>Dinam6812@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Tara</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Umm Al-Banin Hospital, Behjat 16, Behjat Street, Mashhad, Razavi Khorasan Province, Iran.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9144734756</zip>
        <telephone>+98 51 3223 1444</telephone>
        <email>taraf@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women aged 18-45 years with singleton pregnancies at 24-26 weeks of gestation
Diagnosed of gestational diabetes mellitus (GDM) based on an oral glucose tolerance test (OGTT)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Use of medications that interact with metformin or affect blood glucose levels
Serum creatinine greater than 1.2 mg/dl
History of known hypersensitivity to metformin
Heart failure
History of myocardial infarction
Moderate to severe pulmonary disease
Adrenal insufficiency
Pituitary insufficiency</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O24.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Gestational diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Pregnant women diagnosed with gestational diabetes mellitus will receive extended-release metformin (XR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery.</i_keyword>
      <i_keyword>Intervention group:  Pregnant women diagnosed with gestational diabetes mellitus will receive immediate-release metformin (IR). Treatment will be initiated at an oral dose of 500 mg once daily with dinner. The dose will be adjusted according to blood glucose levels and patient tolerability, based on the study protocol. Treatment will continue until delivery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting Blood Glucose. Timepoint: At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery. Method of measurement: FBS will be measured after at least 8 hours of fasting using a glucometer or laboratory blood glucose testing, expressed in mg/dl.</prim_outcome>
      <prim_outcome>One hour Postprandial Blood Glucose. Timepoint: At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery. Method of measurement: Blood Glucose will be measured one hour after the start of a meal, using a glucometer or laboratory blood glucose testing, expressed in mg/dl.</prim_outcome>
      <prim_outcome>Two hour Postprandial Blood Glucose. Timepoint: At baseline ( 24-26 weeks of gestation), during treatment follow up, and at delivery. Method of measurement: Blood Glucose will be measured two hour after the start of a meal, using a glucometer or laboratory blood glucose testing, expressed in mg/dl.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Incidence of adverse effects associated with extended-release and immediate-release metformin. Timepoint: From treatment initiation, during follow-up visits until delivery. Method of measurement: Assessment and recording of patient-reported adverse effects and physician evaluations throughout treatment.</sec_outcome>
      <sec_outcome>Number and percentage of patients requiring insulin therapy due to inadequate glycemic control with metformin. Timepoint: From metformin initiation, during follow-up visits until delivery. Method of measurement: Review of medical records to identify patients who require initiation of insulin therapy due to inadequate glycemic control, based on the treating physician’s assessment.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-21</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Ahmadabad Street, Ghaem Hospital, Mashhad, Iran. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
